Apoptosis in hepatitis C

Journal of Viral Hepatitis

Volumn 10, Issue 5, 2003, Pages 335-342

  Kountouras, Jannis ^a,b   Zavos, C ^a   Chatzopoulos, D ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

Apoptosis; Caspases; Gene therapy; Hepatitis C; Molecular immunology

Indexed keywords

AMINOTRANSFERASE; ANTIVIRUS AGENT; CASPASE; CORE PROTEIN; INTERFERON;

APOPTOSIS; CELL NUCLEUS; CELL STRUCTURE; CORRELATION ANALYSIS; CYTOPLASM; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; FRAGMENTATION REACTION; HEPATITIS; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL; LIVER HISTOLOGY; MONITORING; PATHOGENESIS; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VIRUS CELL INTERACTION;

ANTIGENS, CD95; ANTIVIRAL AGENTS; APOPTOSIS; CASPASES; FAS LIGAND PROTEIN; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; INTERFERONS; MEMBRANE GLYCOPROTEINS; T-LYMPHOCYTES; URSODEOXYCHOLIC ACID; VIRAL CORE PROTEINS;

EID: 0141427999     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2003.00452.x     Document Type: Review

References (39)

1. Marusawa H, Hijikata M, Chiba T, Shimotohno K. Hepatitis C Virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-κB activation. J Virol 1999; 73: 4713-4720.
2. Bantel H, Lugering A, Poremba C et al. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 2001; 34: 758-767.
3. Patel T, Steer CJ, Gores GJ. Apoptosis and the liver: a mechanism of disease, growth regulation, and carcinogenesis. Hepatology 1999; 30: 811-815.
4. Miyaguchi S, Watanabe T, Takahashi H, Nakamura M, Saito H, Ishii H, Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. Hepatogastroenterology 2002; 49: 724-729.
5. Luo JC, Hwang SJ, Chang FY et al. Simple blood tests can predict compensated liver cirrhosis in patients with chronic hepatitis C. Hepatogastroenterology 2002; 49: 478-481.
6. Khan MA, Poulos JE, Brunt EM et al. Hepatic α-smooth muscle actin expression in hepatitis C patients before and after interferon therapy. Hepatogastroenterology 2001; 48: 212-215.
7. Giannini E, Arzani L, Borro P et al. Does surveillance for hepatocellular carcinoma in HCV cirrhotic patients improve treatment outcome mainly due to better clinical status at diagnosis? Hepatogastroenterology 2000; 47: 1395-1398.
8. Boker KH, Pehle B, Steinmetz C, Breitenstein K, Bahr M, Lichtinghagen R. Tissue inhibitors of metalloproteinases in liver and serum/plasma in chronic active hepatitis C and HCV-induced cirrhosis. Hepatogastroenterology 2000; 47: 812-819.
9. Srinivas D, Mani H, Crumpler C, Van Thiel DH. Daily interferon therapy for chronic hepatitis C: a report of a community practice experience. Hepatogastroenterology 2002; 49: 1053-1057.
10. Calabrese F, Pontiso P, Perrenazzo E et al. Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepatology 2000; 31: 1153-1159.
11. Que FG, Gores GJ. Cells death and apoptosis: basic concepts and disease relevance for the gastroenterologist. Gastroenterology 1996; 110: 1238-1243.
12. Kountouras J, Boura P, Lygidakis NJ. Liver regeneration after hepatectomy. Hepatogastroenterology 2001; 48: 556-562.
13. Kountouras J, Zavos C, Chatzopoulos D. Apoptosis in hepatocellular carcinoma. Hepatogastroenterology 2003; 50: 242-249.
14. Rust C, Gores GJ. Apoptosis and liver disease. Am J Med 2000; 108: 567-574.
15. Lau JYN, Xie X, Lai MMC, Wu PC. Apoptosis and viral hepatitis. Semin Liver Dis 1998; 18: 169-176.
16. Muratori L, Gibellini D. A new route to apoptosis in hepatitis C virus infection. J Hepatol 2001; 35: 814-815.
17. Toubi E, Kessel A, Goldstein L et al. Enhanced peripheral T-cell apoptosis in chronic hepatitis C virus infection: association with liver disease severity. J Hepatol 2001; 35: 774-780.
18. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997; 326: 1-16.
19. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NFκB. Proc Natl Acad Sci USA 2001; 98: 9599-9604.
20. Budd RC. Activation-induced cell death. Curr Opin Immunol 2001; 13: 356-362.
21. Los M, Stroh C, Janicke RU, Engels IHH, Schutze-Osthoff K. Caspases: more than just killers? Trends Immunol 2001; 22: 31-34.
22. Ryo K, Kamogawa Y, Ikeda I et al. Fas and FasL strongly expressed in liver of fulminant hepatitis patients. Hepatology 1995; 22: 230A
23. Jarmay K, Karacsony G, Ozsvar Z, Nagy I, Lonovics J, Schaff Z. Assessment of histological features in chronic hepatitis C. Hepatogastroenterology 2002; 49: 239-243.
24. Hahn YS, Soguero C, Cruise M. Towards a reliable parameter of liver damage in hepatitis C: TUNEL versus caspase activation. Hepatology 2001; 34: 840-841.
25. Botarelli P, Brunetto MR, Minutello MA et al. T-cell response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993; 194: 580-587.
26. Sugimura T, Motomura S, Sakai H, Nawata H. Increased serum soluble IL-2 receptor levels following interferon therapy in patients with chronic hepatitis C. Hepatogastroenterology 1999; 46: 1827-1830.
27. Hatano E, Bennett BL, Manning AM, Qian T, Lemasters JJ, Brenner DA. NFκB stimulates inducible nitric oxide synthase to protect mouse hepatocytes from TNFα and Fas-mediated apoptosis. Gastroenterology 2001; 120: 1251-1262.
28. Kawamura C, Nakajima S, Kuroki T, Monna T. Two-dimensional analysis of production of IL-6 and TNF-alpha can predict the efficacy of IFN-alpha therapy. Hepatogastroenterology 1999; 46: 2941-2945.
29. Kato N, Yoshida H, Ono-Nita SK et al. Activation of intra-cellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology 2000; 32: 405-412.
30. Dincer D, Okten A, Kaymakoglu S et al. Persistently normal alanine transaminase levels in chronic C hepatitis: what does it tell us? Hepatogastroenterology 2001; 48: 1397-1400.
31. Yagura M, Murai S, Kojima H, Tokita H, Kamitsukasa H, Harada H. Interferon treatment in patients with chronic hepatitis C with normal alanine-aminotransferase activity. Hepatogastroenterology 1999; 46: 1094-1099.
32. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107.
33. Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of rebavirin and interferon alpha on viral turnover. Hepatology 1998; 28: 245-252.
34. Kronenberger B, Ruster B, Lee JH et al. Hepatocellular proliferation in patients with chronic hepatitis C and persistently normal or abnormal aminotransferase levels. J Hepatol 2000; 33: 640-647.
35. Okazaki M, Hino K, Fujii K, Kobayashi N, Okita K. Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 1996; 41: 2453-2458.
36. Castelli JC, Hassel BA, Wood KA et al. A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. J Exp Med 1997; 186: 967-972.
37. Colell A, Coll O, Garcia-Ruiz C et al. Tauroursodeoxycholic acid protects hepatocytes from ethanol-fed rats against tumor necrosis factor-induced cell death by replenishing mitochondrial glutathione. Hepatology 2001; 34: 964-971.
38. Takikawa Y, Miyoshi H, Rust C et al. The bile acid-activated phosphatidylinositol 3-kinase pathway inhibits Fas apoptosis upstream of Bid in rodent hepatocytes. Gastroenterology 2001; 120: 1810-1817.
39. Fabbri C, Marchetto S, Pezzoli A et al. Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients. Eur J Gastroenterol Hepatol 2000; 12: 511-515.